TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER WITH LIVER METASTASES WITH AN ANTI PD-L1 ANTIBODY AND AN ONCOLYTIC VIRUS

• 1. 用抗PD-L1抗体和溶瘤病毒治疗三阴性乳癌或结肠直肠癌伴随肝转移 [P] . 中国专利： CN111246883A . 2020-06-05
• 2. 在抗PD-L1/PD1治疗失败之后抗CSF-1R抗体与抗PD-L1抗体组合对肿瘤的治疗 [P] . 中国专利： CN110072553A . 2019-07-30
• 3. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti PD-L1 antibody and an oncolytic virus [P] . AU2018314227A8 . 2020-10-08

  机译： 抗PD-L1抗体和溶瘤病毒治疗具有肝转移的三阴性乳腺癌或大肠癌

• 4. TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER WITH LIVER METASTASES WITH AN ANTI PD-L1 ANTIBODY AND AN ONCOLYTIC VIRUS [P] . CA3071599A1 . 2019-02-14

  机译： 肝转移性抗PD-L1抗体和溶瘤病毒治疗三阴性乳腺癌或大肠癌

• 5. TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER WITH LIVER METASTASES WITH AN ANTI PD-L1 ANTIBODY AND AN ONCOLYTIC VIRUS [P] . 世界知识产权组织专利： WO2019032431A1 . 2019-02-14

  机译： 肝转移性抗PD-L1抗体和溶瘤病毒治疗三阴性乳腺癌或大肠癌

• 1. Time-Programmed Delivery of Sorafenib and Anti-CD47 Antibody via a Double-Layer-Gel Matrix for Postsurgical Treatment of Breast Cancer [J] . Liping Huang, Yiyi Zhang, Yanan Li, 纳微快报：英文版 . 2021,第009期
• 2. Establish and authenticate an animal model for the triple negative breast cancer with high expression of PD-L1 and EGFR [J] . Shi-Jian Wang, Li Li, Tie-Feng Xu 海南医科大学学报（英文版） . 2019,第002期
• 3. Oncolytic poxvirus CF33-hNIS-Delta F14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model [J] . Progress in Artificial Intelligence . 2020,第1期
• 4. Oncolytic poxvirus CF33-hNIS-AF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model [J] . Shyambabu Chaurasiya, Annie Yang, Seonah Kang, Oncoimmunology. . 2020,第1期
• 5. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer (vol 148, pg 489, 2014) [J] . Gholami Sepideh, Marano Andrew, Chen Nanhai G., Breast cancer research and treatment. . 2016,第3期
• 6. Co-delivery of chemo drug and siRNA using layer-by-layer nanoparticles for triple negative breast cancer treatment [C] . Jason Z. Deng, Stephen Morton, Paula Hammond Society for biomaterials annual meeting and exposition . 2013
• 7. Drug Delivery Strategies for Treatment of Triple Negative Breast Cancer, Ocular Diseases and Biofabrication of Invitro Models [D] . Kutlehria, Shallu. 2020
• 8. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model [O] . Shyambabu Chaurasiya, Annie Yang, Seonah Kang, 2020
• 9. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer [O] . Sepideh Gholami, Andrew Marano, Nanhai G. Chen, 2014
• 10. Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Technology Assessment Report [R] . Terasawa, T., Dahabreh, I., Castaldi, P. J., 2010

• 1. Trans-arterial chemoperfusion for the treatment of liver metastases of breast cancer and colorectal cancer: Clinical results in palliative care patients [J] . Tatjana Gruber-Rouh ,Marcel Langenbach ,Nagy NN Naguib . 世界临床肿瘤学杂志：英文版 . 2017,第4期
• 2. Time-Programmed Delivery of Sorafenib and Anti-CD47 Antibody via a Double-Layer-Gel Matrix for Postsurgical Treatment of Breast Cancer [J] . Liping Huang ,Yiyi Zhang ,Yanan Li . 安徽地质 . 2021,第009期
• 3. Combination Therapy of Capecitabine with Cyclophosphamide as a Second-Line Treatment after Failure of Paclitaxel plus Bevacizumab Treatment in a Human Triple Negative Breast Cancer Xenograft Model [J] . Mieko Yanagisawa ,Keigo Yorozu ,Mitsue Kurasawa . 癌症治疗（英文） . 2013,第7期
• 4. 三阴性乳腺癌分子亚型与抗转移治疗优化策略 [C] . 应明真 ,王雅杰 . 第八届中国肿瘤内科大会、第三届中国肿瘤医师大会暨中国抗癌协会肿瘤临床化疗专业委员会2014年学术年会 . 2014
• 5. PD-1/PD-L1抑制剂联合化疗治疗三阴性乳腺癌有效性和安全性的系统评价和Meta分析 [A] . 谢潇 . 2021